Interleukin-15	B:C0254610
as	O
a	O
potential	O
new	O
target	O
in	O
Sjögren	B:C1527336
's	I:C1527336
syndrome	I:C1527336
-	O
associated	O
inflammation	B:C0021368
.	O

IL	B:C0254610
-	I:C0254610
15	I:C0254610
is	O
a	O
key	O
regulatory	B:C0079189
cytokine	I:C0079189
that	O
shares	O
many	O
biological	O
properties	O
with	O
IL	B:C0021756
-	I:C0021756
2	I:C0021756
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
IL	B:C0254610
-	I:C0254610
15	I:C0254610
could	O
be	O
up	B:C0041904
-	I:C0041904
regulated	I:C0041904
in	O
T	B:C0039194
cell	I:C0039194
-	O
mediated	O
inflammatory	B:C1290884
disorders	I:C1290884
,	O
such	O
as	O
rheumatoid	B:C0003873
arthritis	I:C0003873
and	O
inflammatory	B:C0021390
bowel	I:C0021390
diseases	I:C0021390
.	O

However	O
,	O
the	O
role	O
and	O
expression	B:C0017262
of	O
IL	B:C1334105
-	I:C1334105
15	I:C1334105
in	O
the	O
inflammatory	B:C0004364
autoimmune	I:C0004364
disease	I:C0004364
Sjögren	B:C1527336
's	I:C1527336
syndrome	I:C1527336
(	O
Sjögren	B:C1527336
's	I:C1527336
syndrome	I:C1527336
)	O
has	O
not	O
been	O
investigated	O
.	O

In	O
the	O
present	O
study	B:C2603343
we	O
evaluated	O
the	O
expression	B:C0017262
of	O
IL	B:C1334105
-	I:C1334105
15	I:C1334105
mRNA	I:C1334105
and	O
protein	B:C0254610
in	O
minor	B:C0036099
salivary	I:C0036099
gland	I:C0036099
(	O
minor	B:C0036099
salivary	I:C0036099
gland	I:C0036099
)	O
biopsy	B:C0677862
specimens	I:C0677862
and	O
in	O
human	B:C0086418
salivary	B:C0036098
gland	I:C0036098
epithelial	B:C0014597
cell	I:C0014597
(	O
salivary	B:C0014597
gland	I:C0014597
epithelial	I:C0014597
cell	I:C0014597
)	O
cultures	O
obtained	O
from	O
patients	O
with	O
primary	B:C0151449
SS	I:C0151449
(	O
primary	B:C0151449
SS	I:C0151449
)	O
and	O
compared	O
their	O
expression	B:C0017262
with	O
that	O
seen	O
in	O
normal	O
healthy	O
control	O
subjects	O
.	O

IL	B:C1334105
-	I:C1334105
15	I:C1334105
gene	I:C1334105
and	O
protein	B:C0254610
analysis	B:C0936012
revealed	O
that	O
salivary	B:C0014597
gland	I:C0014597
epithelial	I:C0014597
cell	I:C0014597
are	O
able	O
to	O
produce	O
IL	B:C0254610
-	I:C0254610
15	I:C0254610
.	O

Results	O
obtained	O
demonstrated	O
that	O
the	O
number	O
of	O
IL	B:C1334105
-	I:C1334105
15	I:C1334105
(+	I:C1334105
)	I:C1334105
cultured	B:C0007635
SGEC	I:C0007635
was	O
significantly	O
higher	O
in	O
cells	B:C0007634
derived	O
from	O
patients	O
with	O
primary	B:C0151449
SS	I:C0151449
in	O
comparison	O
with	O
salivary	B:C0014597
gland	I:C0014597
epithelial	I:C0014597
cell	I:C0014597
from	O
healthy	B:C1708335
subjects	I:C1708335
;	O
similar	O
results	O
were	O
obtained	O
for	O
IL	B:C0254610
-	I:C0254610
15	I:C0254610
immunoreactivity	O
by	O
using	O
immunohistochemistry	B:C0021044
that	O
revealed	O
a	O
strong	O
expression	B:C0017262
both	O
in	O
acinar	B:C0596030
and	O
in	O
ductal	B:C1179554
cells	I:C1179554
from	O
primary	B:C0151449
SS	I:C0151449
minor	B:C0036099
salivary	I:C0036099
gland	I:C0036099
.	O

These	O
studies	O
could	O
provide	O
a	O
rational	O
basis	O
to	O
determine	O
whether	O
IL	B:C0254610
-	I:C0254610
15	I:C0254610
could	O
be	O
a	O
good	O
candidate	O
for	O
anti-cytokine	B:C0281178
therapy	I:C0281178
in	O
chronic	B:C0021376
inflammatory	I:C0021376
primary	B:C0151449
SS	I:C0151449
diseases	B:C0012634
.	O

